entX Limited has entered into an Radioisotope Supply Agreement with Telix Pharmaceuticals for the supply of high-purity Thorium-228 (Th-228) and Radium-226 (Ra-226), supporting the advancement of next-generation targeted radiopharmaceutical therapies utilising Lead-212 (Pb-212) and Actinium-225 (Ac-225).

The agreement represents a significant milestone in entX’s strategy to build sovereign Australian manufacturing capability across the radiopharmaceutical supply chain, while strengthening partnerships within the global nuclear medicine sector.

Telix is a global biopharmaceutical company focused on the development and commercialisation of targeted radiopharmaceutical therapies and precision medicine solutions. The collaboration highlights the increasing importance of secure and reliable isotope supply as global demand for targeted cancer therapies continues to grow.

For entX, the agreement validates the company’s production capabilities and reinforces its commitment to establishing sovereign Australian capability across the radiopharmaceutical supply chain - from isotope production through to advanced healthcare applications.

Managing Director Bryn Jones said the agreement reflects continued momentum in entX’s healthcare strategy and growing recognition of the company’s capabilities within the nuclear medicine sector.

“We are thrilled to partner with Telix, combining our expertise in radioisotope production with their leadership in radiopharmaceuticals to support the advancement of next-generation therapies,” Mr Jones said.

Through reliable manufacturing capability at its Advanced Radioisotope Manufacturing Facility (ARMF) in Adelaide, Australia, entX is building the infrastructure, expertise, and operational track record required to support a broader international customer base and contribute to the expansion of radiopharmaceutical pipelines globally.

The agreement also aligns with entX’s broader “Mines to Medicine” strategy, focused on unlocking value from Australia’s natural resources to support healthcare, defence, and advanced technology applications.

entX looks forward to working alongside Telix to support innovation, strengthen isotope supply chain capability, and ultimately improve patient outcomes worldwide.